We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Gut Microbiome Analysis Predicts Hospitalizations in Cirrhosis

By LabMedica International staff writers
Posted on 11 Apr 2018
Cirrhosis is a leading cause of mortality and healthcare expenditure due to hospitalizations worldwide. More...
Bacterial products such as endotoxin play a key role in the development of a proinflammatory milieu and disease progression in cirrhosis.

Specifically, the development of hepatic encephalopathy (HE) and spontaneous bacterial peritonitis (SBP) has a strong gut-based origin. A growing body of literature has linked gut microbial DNA results with negative outcomes in cirrhosis.

Scientists at the Virginia Commonwealth University (Richmond, VA, USA) and their colleagues carried out a prospective study of patients with cirrhosis defined through biopsy, features of decompensation, endoscopic or radiological evidence of varices or cirrhosis in the setting of chronic liver disease. Stool collection for DNA and RNA was performed using Parapak and stool was stored in RNAlater until it was ultimately extracted.

The reverse bacterial 16S primer (1492R) was used to make the cDNA. Both DNA and cDNA were used in polymerase chain reaction (PCRs) with universal bacterial primers for the first two variable regions L27F and 355R. DNA or cDNA was amplified by PCR for sequencing using Ion Torrent technology. Prepared diluted samples were separated on an ABI 3130xl fluorescent capillary sequencer.

The team included 26 controls and 154 cirrhotics including 54 infected, 62 decompensated, 20 renal dysfunctions, and 18 treated with rifaximin in the study. RNA and DNA analysis showed differing potentially pathogenic taxa but similar autochthonous taxa composition. Thirty subjects underwent the omeprazole study, which demonstrated differences between RNA and DNA changes. Thirty-six patients were hospitalized within 90 days. In the RNA model, Model for End-Stage Liver Disease (MELD) score and Enterococcus were independently predictive of hospitalizations, while in the DNA model MELD was predictive and Roseburia protective. In both models, adding microbiota significantly added to the MELD score in predicting hospitalizations.

Jasmohan Bajaj, MD, the lead author of the study, said, “The hospitalizations that take place with cirrhosis are exorbitantly expensive. Anything that helps us predict the likelihood of hospitalization is better than the status quo. One of the major sources of inflammation in patients with cirrhosis or individuals who are obese is pathogenic bacteria, so, we began looking at gut microbes. People with cirrhosis who are hospitalized tend to get a very big inflammatory surge in their body because of infections and other organ failures.” The study was published on March 8, 2018, in the journal JCI Insight.

Related Links:
Virginia Commonwealth University


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR Setup
ESTREAM
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.